Iveric Bio to Report First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
Iveric Bio, Inc. (Nasdaq: ISEE) will release its Q1 2021 financial and operational results on May 5, 2021. A conference call is scheduled for 8:00 a.m. Eastern Time to discuss these results and provide a business update. Participants can dial 1-888-317-6003 (USA) or 1-412-317-6061 (International) with passcode 5841649. The call will also be accessible via a live audio webcast on the Iveric Bio website, with a replay available for two weeks. Iveric Bio focuses on developing treatments for retinal diseases.
- Scheduled release of Q1 2021 financial results indicates transparency and communication with investors.
- Focus on retinal disease treatments aligns with significant unmet medical needs, potentially capturing market interest.
- Lack of specific financial metrics or guidance in the announcement may raise concerns about future performance.
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 5841649. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 1-877-344-7529 (USA Toll Free), passcode 10153477.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release. Iveric Bio anticipates that subsequent events and developments will cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.
ISEE-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005187/en/
FAQ
When will Iveric Bio report its Q1 2021 financial results?
What time is the Iveric Bio conference call for Q1 results?
How can I access the Iveric Bio Q1 2021 conference call?
Will there be a replay of the Iveric Bio conference call?
What is the focus of Iveric Bio's business?
